Page last updated: 2024-11-10

streptomyces pepsin inhibitor

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID5481345
CHEMBL ID301728
SCHEMBL ID10777706
MeSH IDM0062535

Synonyms (28)

Synonym
acetyl pepstatin
(3s,4s)-4-[[(2s)-2-[[(3s,4s)-4-[[(2s)-2-[[(2s)-2-acetamido-3-methyl-butanoyl]amino]-3-methyl-butanoyl]amino]-3-hydroxy-6-methyl-heptanoyl]amino]propanoyl]amino]-3-hydroxy-6-methyl-heptanoic acid
28575-34-0
acetylpepstatin
acetyl-pepstatin
pepsin inhibitor (streptomyces naniwaensis)
pepstatin a, 1-(n-acetyl-l-valine)-
l-valinamide, n-acetyl-l-valyl-n-[(1s,2s)-4-[[(1s)-2-[[(1s)-1-[(1s)-2-carboxy-1-hydroxyethyl]-3-methylbutyl]amino]-1-methyl-2-oxoethyl]amino]-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-
s-pi (pepsin inhibitor)
pepsin inhibitor s-pi-d (8ci)
pepsidin c
pepstatin ac
pepsidine c
l-alaninamide, n-acetyl-l-valyl-l-valyl-(3s,4s)-4-amino-3-hydroxy-6-methylheptanoyl-n-[(1s)-1-[(1s)-2-carboxy-1-hydroxyethyl]-3-methylbutyl]- (9ci)
s-pi
5HVP
n-acetyl pepstatin
CHEMBL301728
(3s,4s)-4-[[(2s)-2-[[(3s,4s)-4-[[(2s)-2-[[(2s)-2-acetamido-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-6-methylheptanoyl]amino]propanoyl]amino]-3-hydroxy-6-methylheptanoic acid
bdbm50368642
SCHEMBL10777706
DTXSID70182781
AKOS027470304
J-017129
mfcd00214071
HY-P1436
CS-0033333
l-valinamide, n-(3-methyl-1-oxobutyl)-l-valyl-n-[4-[[2-[[1-(2-carboxy-1-hydroxyethyl)-3-methylbutyl]amino]-1-methyl-2-oxoethyl]amino]-2-hydroxy-1-(2-methylpropyl)-4-oxobutyl]-, monoacetate (ester), [1s-[1r*,2r*,4[r*[r*(r*)]]]]- (9ci)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HIV-1 PROTEASEHuman immunodeficiency virus 1Ki0.02000.02000.02000.0200AID977610
Chain B, HIV-1 PROTEASEHuman immunodeficiency virus 1Ki0.02000.02000.02000.0200AID977610
Genome polyprotein Human rhinovirus sp.Ki0.00500.00010.01650.1000AID163466
Protease Human immunodeficiency virus 1Ki0.02520.00000.04433.1000AID160616; AID160777; AID162713
Protease Human immunodeficiency virus 1IC50 (µMol)0.24000.00000.81769.8500AID1540971
Protease Human immunodeficiency virus 1Ki0.55000.00000.02841.1000AID339768; AID698064
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protease Human immunodeficiency virus 1Kd3.03900.00000.61178.1500AID673196; AID673197; AID673198
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1180666Inhibition of bovine spleen cathepsin B using Z-Arg-Arg-AMC as substrate after 30 mins by fluorescence assay2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Lower homologues of ahpatinin, aspartic protease inhibitors, from a marine Streptomyces sp.
AID162713Binding affinity against HIV-1 aspartic proteinase was determined1993Journal of medicinal chemistry, Jul-23, Volume: 36, Issue:15
Multiple copy simultaneous search and construction of ligands in binding sites: application to inhibitors of HIV-1 aspartic proteinase.
AID1540971Inhibition of HIV1 protease expressed in Escherichia coli using Abz-Ala-Arg-Val-Nle-Tyr(NO2)-Glu-Ala-Nle-NH2 peptide as substrate by FRET assay2019Journal of natural products, 10-25, Volume: 82, Issue:10
Oleanolic Acid Derivatives as Potential Inhibitors of HIV-1 Protease.
AID1675165Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability at >90 uM after 48 hrs2020Journal of natural products, 08-28, Volume: 83, Issue:8
Bioactive Lignans from
AID160777Binding affinity to HIV-1 protease1994Journal of medicinal chemistry, Jun-10, Volume: 37, Issue:12
Three-dimensional pharmacophores from binding data.
AID379280Inhibition of HIV1 protease at 100 ug/ml2000Journal of natural products, Feb, Volume: 63, Issue:2
Inhibitory effects on HIV-1 protease of constituents from the wood of Xanthoceras sorbifolia.
AID1675170Cytotoxicity against human MCF7 cells assessed as reduction in cell viability at <90 uM after 48 hrs2020Journal of natural products, 08-28, Volume: 83, Issue:8
Bioactive Lignans from
AID379279Inhibition of HIV1 protease2000Journal of natural products, Feb, Volume: 63, Issue:2
Inhibitory effects on HIV-1 protease of constituents from the wood of Xanthoceras sorbifolia.
AID673198Binding affinity to Human immunodeficiency virus 1 protease by SPR biosensor interaction analysis at pH 4.12012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Experimental and 'in silico' analysis of the effect of pH on HIV-1 protease inhibitor affinity: implications for the charge state of the protein ionogenic groups.
AID339768Inhibition of HIV1 protease2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Is quantum mechanics necessary for predicting binding free energy?
AID698064Inhibition of HIV1 protease2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Rational approaches to improving selectivity in drug design.
AID322905Inhibition of recombinant HIV1 protease at 100 ug/ml2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.
AID163466The compound was tested for its affinity against HIV -2 protease1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
HIV protease: a novel chemotherapeutic target for AIDS.
AID673197Binding affinity to Human immunodeficiency virus 1 protease by SPR biosensor interaction analysis at pH 5.12012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Experimental and 'in silico' analysis of the effect of pH on HIV-1 protease inhibitor affinity: implications for the charge state of the protein ionogenic groups.
AID697798Inhibition of HIV1 protease dimerization expressed in Escherichia coli Rosetta(DE3) at 5 uM by 1-Anilino-8-naphthalene sulfonate-based fluorescent probe binding assay2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Carbonylhydrazide-based molecular tongs inhibit wild-type and mutated HIV-1 protease dimerization.
AID160769Affinity for HIV Protease2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
SMall Molecule Growth 2001 (SMoG2001): an improved knowledge-based scoring function for protein-ligand interactions.
AID673196Binding affinity to Human immunodeficiency virus 1 protease by SPR biosensor interaction analysis at pH 7.42012Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15
Experimental and 'in silico' analysis of the effect of pH on HIV-1 protease inhibitor affinity: implications for the charge state of the protein ionogenic groups.
AID160616Binding affinity for HIV-1 protease1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
HIV protease: a novel chemotherapeutic target for AIDS.
AID1180667Inhibition of porcine gastric mucosa pepsin using MOCAc-Ala-Pro-Ala-Lys-Phe-Phe-Arg-Leu-Lys (Dnp)-NH2 as substrate after 20 mins by fluorescence assay2014Journal of natural products, Jul-25, Volume: 77, Issue:7
Lower homologues of ahpatinin, aspartic protease inhibitors, from a marine Streptomyces sp.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1990The Journal of biological chemistry, Aug-25, Volume: 265, Issue:24
Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution.
AID1811Experimentally measured binding affinity data derived from PDB1990The Journal of biological chemistry, Aug-25, Volume: 265, Issue:24
Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (28.57)18.2507
2000's4 (28.57)29.6817
2010's5 (35.71)24.3611
2020's1 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]